Precision BioSciences (NASDAQ:DTIL) reported Q2 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $4.97 million.
Precision BioSciences (NASDAQ:DTIL) reported Q2 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $4.97 million.